Milestone Says Licensing Partner Ji Xing Released Topline Results From Trial In China On Etripamil Nasal Spray; Trial Met Its Primary Endpoint
Portfolio Pulse from Benzinga Newsdesk
Milestone Pharmaceuticals announced that its licensing partner, Ji Xing, has released positive topline results from a trial in China for Etripamil nasal spray. The trial met its primary endpoint, indicating potential success for the product.
September 06, 2024 | 11:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Milestone Pharmaceuticals' licensing partner Ji Xing achieved positive results in a trial for Etripamil nasal spray in China, meeting the primary endpoint. This success could enhance Milestone's market position and product portfolio.
The successful trial results for Etripamil nasal spray in China, conducted by Milestone's partner Ji Xing, suggest a positive outlook for the product's market potential. This could lead to increased investor confidence and a potential rise in Milestone's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80